Vemurafenib is FDA-approved for metastatic and unresectable melanoma with V600 mutation and Erdheim- Chester disease (non-Langerhans histiocytic disorder). Non-FDA-labeled Indications include metastatic and unresecctable melanoma with BRAF V600K and refractory non-small cell lung carcinoma BRAF V600 mutation. This activity provides an overview of the indications, mechanism of action, methods and timing of administration, important adverse effects, contraindications, toxicity, and monitoring for vemurafenib as chemotherapy for indicated cancers.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/36012
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), Ambulatory/Outpatient, Complex General Surgical Oncology, General Operative Anesthesia, General Pediatrics, General Surgery, Internal Medicine, Medical Oncology, Non-Thoracic Surgery, Pediatric Hematology-Oncology, Pulmonary Disease
Subscribe
Login
0 Comments
Oldest